The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

The stock's fall snapped a two-day winning streak.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

The biopharma company—whose US headquarters is in Atlanta—will be building a new biologics manufacturing facility in a city ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million ...

"It's cool to get the award, but what I submitted to it is so much more important to me," Cooper Taylor said about getting a ...

23andMe struck a deal last month with Regeneron Pharmaceuticals Inc., but Wojcicki complained about the bidding process, ...